Eris Lifesciences Ltd.

₹1,335

10.3 (0.8%)

ERIS Share Price

Pharmaceuticals & Biotechnology

As on September 9, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 18,360 Cr

P/E Ratio29.62

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,321.84	Bullish
10-DMA	1,312.22	Bullish
20-DMA	1,325.42	Bullish
50-DMA	1,380.18	Bearish
100-DMA	1,381.63	Bearish
200-DMA	1,413.64	Bearish

Historical Performance

1 Year

-22.6%

3 Years

60.4%

5 Years

72%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	31,294	28,936	20,092	16,852	13,470
Total Expenditure	20,200	18,764	13,343	11,484	8,620
Other Income	185	184	238	112	261
Operating Profit	11,279	10,356	6,987	5,479	5,111
Interest	1,927	2,313	848	262	42
Depreciation	2,795	3,155	1,825	1,171	647
Profit Before Tax	6,385	4,889	4,313	4,046	4,422
Consolidated Net Profit	6,195	3,518	3,920	3,822	4,061
Adjusted EPS	45	26	29	28	30

Compounded Sales Growth

10 Years:39.3

5 Years:20.9

3 Years:13.2

TTM:1.6

Compounded Profit Growth

10 Years:35.9

5 Years:11.8

3 Years:10.1

TTM:12

Stock Price CAGR

10 Years:N/A

5 Years:11.7

3 Years:17.4

TTM:-22.1

Return on Equity

10 Years:17.9

5 Years:29.9

3 Years:28.8

last year:44.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	139	136	136	136	136
Total Reserves	38,746	28,306	25,676	21,796	18,928
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	11,498	21,010	9,793	7,300	-788
Other Current Liabilities	11,781	5,340	9,002	1,901	358
Short Term Borrowings	4,539	3,966	13,113	550	---
Total Liabilities	72,467	68,655	68,104	34,719	21,127
Capital Work in Progress	1,715	667	191	214	240
Long Term Loans & Advances	1,517	883	698	253	359
Currents Investments	---	50	---	300	995
Short Term Loans and Advances	4,355	2,873	3,351	3,076	2,562
Total Current Assets	16,640	13,344	23,789	8,427	7,110
Total Assets	72,467	68,655	68,104	34,719	21,127
Adjusted Book Value	281	209	190	161	140

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 29.62, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 17.5%, indicating sustained price appreciation.
The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹11279 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹31294 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 779016.2

No. of Shares: 584 (Approx)

Performance:-22.1%

-220983.8

NIFTY Performance: -6.2%

1 day Top Gainers